Navigation Links
Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections
Date:12/19/2007

patients and investors in Axentis."

Mr. Toru Gensuke Tokoro, President and CEO of aRigen Pharmaceuticals, Inc. adds: "ARB-CF0223 is based on a well-characterised drug, Tobramycin. Utilising synthetic liposomes that contain Tobramycin, a proprietary nebulizer delivers the drug directly to the endobronchial sites of infection in Cystic Fibrosis patients. This results in prolonged, high local drug concentration, which in turn achieves higher efficacy and lower doses. We are pleased that a competent partner such as Axentis Pharma will further develop this promising product."

The drug has already been tested successfully in a phase I single-dose inhalation study. No significant adverse events were observed when the liposomal formulation of Tobramycin was compared with the currently marketed formulation in 24 healthy volunteers who were treated in a crossover fashion.

About Cystic Fibrosis

Cystic Fibrosis (CF) is the most common life-threatening inherited multi-organ disease in Caucasians and is caused by a mutation in the CFTR-gene (cystic fibrosis transmembrane conductance regulator) on chromosome 7. The defective gene leads to viscous secretions and impaired mucociliary clearance. The most devastating clinical consequence of CF and cause of morbidity and mortality is lung involvement. A striking feature of lung involvement is the endobronchial colonisation with the bacterial strain Pseudomonas aeruginosa. Chronic inflammation contributes to obstructive lung disease and tissue destruction leading to bronchiectasis and respiratory failure.

About Axentis Pharma AG (http://www.axentispharma.com)

Axentis Pharma AG is a Swiss biotech company. The company owns proprietary technology used in the treatment of diseases, the etiology of which is misrouted or misfolded proteins, for example, cystic fibrosis, nephrogenic diabetes insipidus, hypercholesterolemia and others. Axentis is
'/>"/>

SOURCE Axentis Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
3. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
6. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
7. Pharsight Achieves First License Sale for Public-Source Database
8. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
9. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
10. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 Research and Markets ... Chinese Stem Cell Industry Report, 2014-2017" report to ... biological cells that can differentiate into specialized cells and ... Stem cell therapy can be applied to treatment of ... nervous system diseases, damage or lesion of liver, kidney ...
(Date:9/18/2014)... September 18, 2014 Leatherwood Plastics ... listed material, to stay competitive in the semiconductor, ... high-performance materials ultimately impact product quality and productivity, ... owner. , Established in 1980 in Lewisville, TX, ... many fabricators have left the business. Much of ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... previously announced concurrent but separate underwritten offerings of 10,000,000 ... the public of $2.00 per share, for expected gross ... Series A Convertible Preferred Stock at a price to ... proceeds of $20 million. Each share of Series A ...
(Date:9/18/2014)... SeqLL Inc., the owner of ... today the closing of a $1M Series-A funding ... Diagnostic Technologies, will increase the power of tSMS™ ... in March 2013 by Daniel Jones, a former ... BioSciences, SeqLL has continued to offer Helicos’ sequencing ...
Breaking Biology Technology:Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2
... April 7 Transgenomic, Inc. (OTC Bulletin Board: TBIO), ... completed a licensing option with the Dana-Farber Cancer Institute, ... Cold-PCR. This variation of the standard PCR technology ... was invented at Dana-Farber by Dr. Mike Makrigiorgos who ...
... WellGen, Inc. today announced that Dr. Roderick (Roddy) ... Executive Officer. Dr. Carter, 45, takes over ... Chief Executive Officer. Mr. Bertoldi will continue in ... Financial Officer of Amphion Innovations plc (LSE: AMP), a ...
... Inc. today announced that it has secured $38 million ... formation in 2004, the company has raised $92 million ... financing round, which consists of two tranches, was led ... pro rata participation of existing investors Apax Partners, Clarus ...
Cached Biology Technology:Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations 2Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations 3Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations 4Dr. Roddy Carter Named President and Chief Executive Officer of WellGen, Inc. 2Dr. Roddy Carter Named President and Chief Executive Officer of WellGen, Inc. 3Aerovance Secures $38 Million in Equity Financing 2Aerovance Secures $38 Million in Equity Financing 3
(Date:9/18/2014)... ever starts a "frequent flyers" program, fruit flies surely ... laboratory has hosted increasing numbers of fruit fly research ... station in April, and another is scheduled launch to ... to launch in December. , Fruit flies are biomedical ... in space. Model organisms can reveal the basis for ...
(Date:9/18/2014)... have built the first smartphone app that automatically ... trends. In other words, your smartphone knows your ... -- and how that affects you. , The ... and loneliness to their academic performance, also may ... example, to monitor mental health, trigger intervention and ...
(Date:9/18/2014)... which have devastated algal forests in the eastern Mediterranean ... basin if their distribution continues to expand as the ... an international team of researchers led by Dr Adriana ... the Mediterranean Institute for Advanced Studies in Spain, is ... of the team surveyed more than 1000 kilometres of ...
Breaking Biology News(10 mins):Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Tropical fish a threat to Mediterranean Sea ecosystems 2
... -- Weill Cornell Medical College and the Columbia University ... Mortimer D. Sackler, M.D. Prize for Distinguished Achievement in ... Dr. Fernando Nottebohm for his seminal work in songbirds ... Dr. Nottebohm is currently the Dorothea L. Leonhardt ...
... but in an infectious disease, it is insidious. Witness tuberculosis, ... before bursting forth into infection. TB,s stealthy nature has made ... to control it. The World Health Organization estimates that a ... a study led by Stanford scientists has provided new insights ...
... sends the human immune system into overdrive it can ... and thrive inside our digestive system. New research suggests ... significant role in triggering the innate immune system to stay ... in the face of an infection. But exactly how ...
Cached Biology News:Sackler Prize awarded to pioneering neuroscientist 2Sackler Prize awarded to pioneering neuroscientist 3Tuberculosis strain spread by the fur trade reveals stealthy approach of epidemics 2Tuberculosis strain spread by the fur trade reveals stealthy approach of epidemics 3Tuberculosis strain spread by the fur trade reveals stealthy approach of epidemics 4Stress wrecks intestinal bacteria, could keep immune system on idle 2
... The LabChip 3000 drug discovery system ... cell-based assays. Using LabChip technology, ... in a serial, continuous flow fashion. ... quality of results exceeds what is ...
...
...
...
Biology Products: